 Applied DNA Sciences Inc NASDAQ:APDN plans to introduce its Linea 2.0 COVID-19 Assay for the SARS-CoV-2 E and N genes after submitting its validation data to the New York State Department of Health NYSDOH in the next few days. The Company also announced that its EUA-authorized Linea COVID-19 Assay Kit likely exhibits a unique double S-gene target failure specific to the Omicron variant. 